Metraipolis › archive › dc_6d181a97555f

Advancing precision immuno-oncology in melanoma: the synergistic convergence of personalized neoantigen vaccines and multi-omics biomarker profiling — Europe PMC PMID:42136652

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42136652
DOI
10.3389/fimmu.2026.1831047
License (as archived)
solo-consultazione
Archived
2026-11-03T02:49:44.683Z
SHA-256 of the archived text
73c184913cf588141f3b9234330ec88d4e52c37b0fc902e1b5c815a46cdff45c
Stable URL of this page
https://metraipolis.com/documento/dc_6d181a97555f

How to cite

Advancing precision immuno-oncology in melanoma: the synergistic convergence of personalized neoantigen vaccines and multi-omics biomarker profiling — Europe PMC PMID:42136652 — Europe PMC (en), https://europepmc.org/article/MED/42136652 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6d181a97555f (Metraipolis archive dc_6d181a97555f, sha256 73c184913cf588141f3b9234330ec88d4e52c37b0fc902e1b5c815a46cdff45c)
BibTeX
@misc{dc6d181a97555f,
  title = {Advancing precision immuno-oncology in melanoma: the synergistic convergence of personalized neoantigen vaccines and multi-omics biomarker profiling — Europe PMC PMID:42136652},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42136652},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6d181a97555f; sha256 73c184913cf588141f3b9234330ec88d4e52c37b0fc902e1b5c815a46cdff45c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42136652. Agents can read the archived copy with the MCP tool read_document.